Exicure (XCUR) addresses Nasdaq delinquency after delayed Q1 2026 10-Q filing
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Exicure, Inc. reported that Nasdaq notified the company on May 28, 2026 that it was out of compliance with Nasdaq Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended March 31, 2026 was filed late.
The delay was attributed to extra time needed after changes in Exicure’s financial reporting personnel and related procedures. Exicure filed the delayed Form 10-Q on May 29, 2026 and believes this filing brings it back into compliance with the Nasdaq listing rule.
The company describes itself as a biotechnology business that has restructured, suspended prior clinical and development activities, and is now exploring strategic alternatives. Its lead program, obtained through a January 2025 acquisition, is being evaluated for improving stem cell mobilization in multiple myeloma, sickle cell disease, and to support cell and gene therapy.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Nasdaq notice date: May 28, 2026
Delayed Form 10-Q period end: March 31, 2026
10-Q filing date: May 29, 2026
+4 more
7 metrics
Nasdaq notice date
May 28, 2026
Date Nasdaq notified Exicure of non-compliance with Listing Rule 5250(c)(1)
Delayed Form 10-Q period end
March 31, 2026
Quarterly Report on Form 10-Q filing period that was delayed
10-Q filing date
May 29, 2026
Date Exicure filed the delayed Form 10-Q with the SEC
Press release date
June 1, 2026
Date of press release about Nasdaq delinquency notice and 10-Q filing
Form 10-K year end
December 31, 2025
Year-end referenced for Exicure’s Form 10-K in risk factor discussion
Form 10-K filing date
March 25, 2026
Date Exicure filed its Form 10-K for the year ended December 31, 2025
Acquisition month and year
January 2025
Acquisition of clinical-stage biotechnology company for hematologic therapeutics
Key Terms
Nasdaq Listing Rule 5250(c)(1), Quarterly Report on Form 10-Q, strategic alternatives, forward-looking statements, +2 more
6 terms
Nasdaq Listing Rule 5250(c)(1) regulatory
"indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing"
Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.
Quarterly Report on Form 10-Q regulatory
"due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026"
A quarterly report on Form 10-Q is a standardized financial filing public companies must submit to U.S. regulators every three months, summarizing recent financial results, cash flows, balance sheet changes, operations and material risks or legal developments. Investors treat it like a company report card that shows up-to-date facts rather than marketing copy, helping them track performance, spot trends, reassess risk and make buy or sell decisions.
strategic alternatives financial
"the Company is exploring strategic alternatives to maximize stockholder value"
Strategic alternatives are different options a company considers to improve its value or achieve its goals, such as selling the business, merging with another company, or restructuring operations. For investors, understanding these options is important because they can significantly impact the company's future direction and its stock value, often signaling potential changes or opportunities.
forward-looking statements regulatory
"Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
stem cell mobilization medical
"The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease"
hematologic diseases medical
"it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases"
Hematologic diseases are disorders that affect the blood, bone marrow or the systems that make blood work—including red and white blood cells, platelets and clotting. Like problems in a building’s delivery pipes, they disrupt delivery of oxygen, immune defense or clotting and can require long-term treatment, specialized drugs or devices. For investors, these conditions drive demand for diagnostics, therapies and clinical trials, so advances or setbacks can materially affect company revenues and valuations.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2026
____________________
(Exact name of Registrant as specified in its charter)
____________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices)
Registrant’s telephone number, including area code: (847 ) 673-1700
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
On May 28, 2026, Exicure, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.
The Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
The full text of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated by reference in this Item 7.01, including the press release furnished herewith as Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press release dated June 1, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 29, 2026 | EXICURE, INC. | |||||||
| By: | /s/ Jung Soo Kim | |||||||
| Jung Soo Kim | ||||||||
| Chief Executive Officer | ||||||||
Exhibit 99.1
EXICURE ANNOUNCES RECEIPT OF NASDAQ DELINQUENCY NOTICE AND FILING OF FORM 10-Q
REDWOOD CITY, CA – June 1, 2026 - Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.
The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.
The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).
About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com.
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements related to the Company’s review and analysis in connection with the Form 10-Q and the Company’s expectations with respect to its financial results for the three months ended March 31, 2026 and the definitive filing date of the Form 10-Q. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of risks and uncertainties, and other
important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.
Media Contact:
Exicure, Inc.
pr@exicuretx.com
FAQ
What Nasdaq compliance issue did Exicure (XCUR) disclose in this 8-K?
Exicure disclosed it received a Nasdaq notice on May 28, 2026 for not complying with Listing Rule 5250(c)(1) after delaying its Form 10-Q for the quarter ended March 31, 2026. The issue stemmed from additional time needed following changes in financial reporting personnel.
How did Exicure (XCUR) respond to the Nasdaq delinquency notice?
Exicure responded by filing its delayed Form 10-Q for the three months ended March 31, 2026 with the SEC on May 29, 2026. The company states it believes this filing brings it back into compliance with Nasdaq Listing Rule 5250(c)(1) governing timely periodic reports.
Why was Exicure’s Form 10-Q for March 31, 2026 delayed?
The Form 10-Q was delayed primarily because Exicure needed additional time after changes in its financial reporting personnel and related filing procedures. The company attributes the late filing to these internal transitions rather than operational or business performance issues described in this disclosure.
What is Exicure’s current business focus according to the filing?
Exicure describes itself as a historically early-stage biotechnology company that has restructured and suspended clinical and development activities. It is now exploring strategic alternatives and advancing a lead program aimed at improving stem cell mobilization in multiple myeloma, sickle cell disease, and cell and gene therapy settings.
What acquisition does Exicure (XCUR) reference and why is it important?
Exicure notes it acquired a clinical-stage biotechnology company in January 2025 that develops therapeutics for hematologic diseases. This deal provided its lead program, which is being evaluated to enhance stem cell mobilization in multiple myeloma, sickle cell disease, and to support emerging cell and gene therapy approaches.
What forward-looking statements does Exicure highlight in this disclosure?
Exicure states the press release contains forward-looking statements about its review related to the Form 10-Q, expectations for financial results for the quarter ended March 31, 2026, and timing of the definitive 10-Q filing date. These statements are subject to risks described in its Form 10-K and later SEC filings.